Sells Rezdiffra, an oral medicine for adults with a form of liver disease, and develops other potential treatments for that disease.
10-K for FY2025, filed Feb 19, 2026
The company sells Rezdiffra to specialty pharmacies and specialty distributors, which deliver the medicine to patients in the United States.
10-K for FY2025, filed Feb 19, 2026
10-K for FY2025, filed Feb 19, 2026
Year ended December 31, 2025 2024 2023 Customer A 34 % 39 % — % Customer B 22 % 21 % — % Customer C 15 % 14 % — % Customer D 12 % 12 % — %View ↗
No. It lost $288.3M in FY2025.
8-K, filed Jul 30, 2026
Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026…View ↗
From development to sales
The older report described Madrigal as clinical-stage, with resmetirom as its lead product candidate. The latest report describes Rezdiffra as an approved and commercially sold medicine, alongside a pipeline of additional MASH candidates.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 19, 2026Our Focus. We are a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis, or NASH. Our…View ↗
Competes with Novo Nordisk, Inventiva, Roche, Eli Lilly, and Boehringer Ingelheim International
10-K for FY2025, filed Feb 19, 2026Rezdiffra was the first medication approved by both the FDA and EC for the treatment of MASH with moderate to advanced fibrosis. Since…View ↗
Loading...